Login to Your Account



Beigene Inks $233M Deal with Merck for Cancer Drug

By Larry Schuster
Contributing Writer

Wednesday, June 12, 2013
SHANGHAI – Beigene Co. Ltd. has licensed a second-generation BRAF inhibitor as a promising preclinical oncology drug to Merck KGaA, of Darmstadt, Germany, for the treatment of melanoma, colorectal cancer and other cancers.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription